{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:13:42Z","timestamp":1790097222280,"version":"4.0.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Sarcomatoid hepatocellular carcinoma (SHC) is an aggressive malignancy with poor therapeutic outcomes. Current evidence supports radical surgical resection as the primary treatment modality, yet it is associated with prohibitively high postoperative recurrence rates. We report the clinical course of a 66-year-old male diagnosed with SHC. A hepatic mass (4.1 \u00d7 2.7 \u00d7 4.4 cm) was incidentally detected during routine health screening. The patient underwent laparoscopic right posterior sectionectomy, with histopathological confirmation of SHC. Superior mesenteric lymphadenopathy suspicious for metastasis developed 1 month postoperatively. Prophylactic transarterial chemoembolization was initiated, followed by 6-month tyrosine kinase inhibitor (TKI) therapy, achieving disease stabilization. However, lymph nodes progression occurred after TKI discontinuation, confirming metastatic involvement. Subsequent combined therapy (a TKI and an anti-PD-1 antibody) was administered. Notably, the patient self-discontinued treatment after two cycles, yet subsequent imaging revealed complete resolution of metastatic lymphadenopathy. No additional antitumor therapy has been administered, and the patient remains recurrence-free with 18-month overall survival confirmed by recent radiographic surveillance.<\/jats:p>","DOI":"10.3389\/fonc.2025.1591419","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T04:12:35Z","timestamp":1758168755000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Curative response to combined targeted-immunotherapy for post-hepatectomy lymph node metastasis in sarcomatoid hepatocellular carcinoma: case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Pan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ming","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie-Dong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Hai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.864106","article-title":"Epidemiological and clinical characteristics of five rare pathological subtypes of hepatocellular carcinoma","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1212013","article-title":"Surgery after combination therapy with a tyrosine kinase inhibitor and anti-PD-1 antibody in sarcomatoid hepatocellular carcinoma: case report and literature review","volume":"13","author":"Liang","year":"2023","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32396","article-title":"Management and outcomes among patients with sarcomatoid hepatocellular carcinoma: A population-based analysis","volume":"125","author":"Wu","year":"2019","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40880-018-0331-y","article-title":"Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety","volume":"38","author":"Wei","year":"2018","journal-title":"Cancer Commun (London England)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2019.06.031","article-title":"Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis","volume":"45","author":"Chen","year":"2019","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30162","article-title":"Clinical manifestations and outcomes of patients with sarcomatoid hepatocellular carcinoma","volume":"69","author":"Liao","year":"2019","journal-title":"Hepatol (Baltimore Md)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0686","article-title":"Integrated molecular characterization of sarcomatoid hepatocellular carcinoma","volume":"31","author":"Sun","year":"2025","journal-title":"Clin Mol Hepatology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33545","article-title":"Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analyses","volume":"149","author":"Morisue","year":"2021","journal-title":"Int J cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-023-03983-1","article-title":"Dynamic contrast-enhanced CT and clinical features of sarcomatoid hepatocellular carcinoma","volume":"48","author":"He","year":"2023","journal-title":"Abdominal Radiol (New York)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/RCT.0b013e3181591ccd","article-title":"Radiological and clinical features of sarcomatoid hepatocellular carcinoma in 11 cases","volume":"32","author":"Koo","year":"2008","journal-title":"J Comput assisted tomography"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000004121","article-title":"18F-FDG PET\/CT imaging in sarcomatoid hepatocellular carcinoma","volume":"47","author":"Yang","year":"2022","journal-title":"Clin Nucl Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2024.04.061","article-title":"FDG PET\/CT Imaging of sarcomatoid hepatocellular carcinoma: A case report","volume":"47","author":"Chen","year":"2024","journal-title":"Asian J surgery"},{"key":"B13","doi-asserted-by":"publisher","first-page":"23247096221129470","DOI":"10.1177\/23247096221129470","article-title":"Disease control achieved\u00a0using atezolizumab + Bevacizumab in a patient with sarcomatoid hepatocellular carcinoma (SHCC), a rare variant excluded from the IMbrave150 trial","volume":"10","author":"Fencer","year":"2022","journal-title":"J Invest Med High impact Case Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1086908","article-title":"Genetic testing and prognosis of sarcomatoid hepatocellular carcinoma patients","volume":"12","author":"Jia","year":"2022","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2025.0071","article-title":"Genetic insights into sarcomatoid hepatocellular carcinoma: Critical role of ARID2 in pathogenesis and immune feature: Editorial on \u201cIntegrated molecular characterization of sarcomatoid hepatocellular carcinoma\u201d","volume":"31","author":"Nishida","year":"2025","journal-title":"Clin Mol hepatology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4162","article-title":"Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome","volume":"10","author":"Zhang","year":"2021","journal-title":"Cancer Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"100042","DOI":"10.1016\/j.modpat.2022.100042","article-title":"Hepatic sarcomatoid carcinoma is an aggressive hepatic neoplasm sharing common molecular features with its conventional carcinomatous counterparts","volume":"36","author":"Yoshuantari","year":"2023","journal-title":"Modern pathology: an Off J United States Can Acad Pathology Inc"},{"key":"B18","doi-asserted-by":"publisher","first-page":"394","DOI":"10.21037\/atm-21-4322","article-title":"Long-term outcomes and prognosis for patients with sarcomatoid hepatocellular carcinoma","volume":"10","author":"Zhou","year":"2022","journal-title":"Ann Trans Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.18632\/aging.203076","article-title":"Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma","volume":"13","author":"Luo","year":"2021","journal-title":"Aging"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1591419\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T04:12:39Z","timestamp":1758168759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1591419\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":19,"alternative-id":["10.3389\/fonc.2025.1591419"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1591419","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"article-number":"1591419"}}